SCHEMBL27138918

SCHEMBL27138918

O=Cc1ccc2nc(N3C[C@H]4COC[C@H]4C3)ncc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCRTR2 O43614 9/20 0.41
▸ HCRTR1 O43613 8/20 0.41
▸ HTR3A P46098 1/20 0.37
▸ PDE10A Q9Y233 5/20 0.36
▸ TLR4 O00206 1/20 0.35
▸ TLR9 Q9NR96 1/20 0.35
▸ TLR8 Q9NR97 1/20 0.35
▸ TLR7 Q9NYK1 1/20 0.35
▸ ACACB O00763 1/20 0.34
▸ PDE2A O00408 1/20 0.34
▸ RET P07949 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ CSNK1A1 P48729 1/20 0.33
▸ CDK8 P49336 1/20 0.33
▸ GSK3A P49840 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ ACVR1 Q04771 1/20 0.33
▸ CLK4 Q9HAZ1 1/20 0.33
▸ DYRK1B Q9Y463 1/20 0.33
▸ HDAC3 O15379 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30718823 0.88 HTR3A (0.40) HCRTR2HCRTR1HTR3APDE10ATLR4
SCHEMBL27145338 0.88 HTR3A (0.40) HCRTR2HCRTR1HTR3APDE10ATLR4
SCHEMBL27148782 0.84 HTR3A (0.38) HCRTR2HCRTR1HTR3APDE10ATLR4
SCHEMBL27139923 0.82 MTOR (0.39) HCRTR2HCRTR1HTR3APDE10ATLR4
SCHEMBL31413439 0.81 HCRTR2 (0.46) HCRTR2HCRTR1HTR3APDE10AACACB
SCHEMBL27150041 0.81 ALDH3A1 (0.49) HTR3ACLK4
SCHEMBL27152248 0.81 HCRTR2 (0.46) HCRTR2HCRTR1HTR3APDE10AACACB
SCHEMBL27138967 0.81 TLR4 (0.36) HCRTR2HCRTR1HTR3APDE10ATLR4
SCHEMBL27138980 0.80 MTOR (0.36) HCRTR2HCRTR1HTR3ATLR4TLR9
SCHEMBL27147037 0.80 MTOR (0.36) HTR3ATLR4TLR9TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 — — EP disclosed
CN-119325469-A WEE1 degrading compounds and uses thereof 百时美施贵宝公司 2025-01-17 — — CN disclosed
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-29 — — US disclosed
WO-2024006881-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof WEE1, WEE2, PPME1 HCRTR2 4792/4885HCRTR1 4736/4885HTR3A 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback